These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 33213345)

  • 21. CRISPR/Cas9-based epigenome editing: An overview of dCas9-based tools with special emphasis on off-target activity.
    Tadić V; Josipović G; Zoldoš V; Vojta A
    Methods; 2019 Jul; 164-165():109-119. PubMed ID: 31071448
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Application of CRISPR-Cas9 for Long Noncoding RNA Genes in Cancer Research.
    Zhen S; Li X
    Hum Gene Ther; 2019 Jan; 30(1):3-9. PubMed ID: 30045635
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CRISPR/Cas9-mediated genome editing: From basic research to translational medicine.
    Jacinto FV; Link W; Ferreira BI
    J Cell Mol Med; 2020 Apr; 24(7):3766-3778. PubMed ID: 32096600
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Scaffold-mediated non-viral delivery platform for CRISPR/Cas9-based genome editing.
    Chin JS; Chooi WH; Wang H; Ong W; Leong KW; Chew SY
    Acta Biomater; 2019 May; 90():60-70. PubMed ID: 30978509
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CRISPR/Cas9 Gene Editing: From Basic Mechanisms to Improved Strategies for Enhanced Genome Engineering In Vivo.
    Salsman J; Masson JY; Orthwein A; Dellaire G
    Curr Gene Ther; 2017; 17(4):263-274. PubMed ID: 29173169
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CRISPR/Cas based gene editing: marking a new era in medical science.
    Prasad K; George A; Ravi NS; Mohankumar KM
    Mol Biol Rep; 2021 May; 48(5):4879-4895. PubMed ID: 34143395
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A simple, quick, and efficient CRISPR/Cas9 genome editing method for human induced pluripotent stem cells.
    Geng BC; Choi KH; Wang SZ; Chen P; Pan XD; Dong NG; Ko JK; Zhu H
    Acta Pharmacol Sin; 2020 Nov; 41(11):1427-1432. PubMed ID: 32555510
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Applications of CRISPR-Cas9 Technology to Genome Editing in Glioblastoma Multiforme.
    Al-Sammarraie N; Ray SK
    Cells; 2021 Sep; 10(9):. PubMed ID: 34571991
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-CRISPR AcrIIA5 Potently Inhibits All Cas9 Homologs Used for Genome Editing.
    Garcia B; Lee J; Edraki A; Hidalgo-Reyes Y; Erwood S; Mir A; Trost CN; Seroussi U; Stanley SY; Cohn RD; Claycomb JM; Sontheimer EJ; Maxwell KL; Davidson AR
    Cell Rep; 2019 Nov; 29(7):1739-1746.e5. PubMed ID: 31722192
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Applications and advances of CRISPR-Cas9 in cancer immunotherapy.
    Xia AL; He QF; Wang JC; Zhu J; Sha YQ; Sun B; Lu XJ
    J Med Genet; 2019 Jan; 56(1):4-9. PubMed ID: 29970486
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CRISPR/Cas genome editing to optimize pharmacologically active plant natural products.
    Dey A
    Pharmacol Res; 2021 Feb; 164():105359. PubMed ID: 33285226
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Application of CRISPR/Cas9 gene editing technique in the study of cancer treatment.
    Jiang C; Meng L; Yang B; Luo X
    Clin Genet; 2020 Jan; 97(1):73-88. PubMed ID: 31231788
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CRISPR/Cas9 system: a powerful technology for in vivo and ex vivo gene therapy.
    Zhang X; Wang L; Liu M; Li D
    Sci China Life Sci; 2017 May; 60(5):468-475. PubMed ID: 28534255
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Erratic journey of CRISPR/Cas9 in oncology from bench-work to successful-clinical therapy.
    Sarkar E; Khan A
    Cancer Treat Res Commun; 2021; 27():100289. PubMed ID: 33667951
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A stable DNA-free screening system for CRISPR/RNPs-mediated gene editing in hot and sweet cultivars of Capsicum annuum.
    Kim H; Choi J; Won KH
    BMC Plant Biol; 2020 Oct; 20(1):449. PubMed ID: 33004008
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Outlook on the Security and Potential Improvements of CRISPR-Cas9.
    Zha MJ; Cai CE; He PM
    Mol Biotechnol; 2023 Nov; 65(11):1729-1736. PubMed ID: 36881252
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genome editing: A perspective on the application of CRISPR/Cas9 to study human diseases (Review).
    Rodríguez-Rodríguez DR; Ramírez-Solís R; Garza-Elizondo MA; Garza-Rodríguez ML; Barrera-Saldaña HA
    Int J Mol Med; 2019 Apr; 43(4):1559-1574. PubMed ID: 30816503
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genetic Editing of Long Noncoding RNA Using CRISPR/Cas9 Technology.
    Larter K; Yi B; Xi Y
    Methods Mol Biol; 2021; 2372():169-177. PubMed ID: 34417751
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CRISPR/Cas9-Based Genome Editing of HSV.
    Velusamy T; Gowripalan A; Tscharke DC
    Methods Mol Biol; 2020; 2060():169-183. PubMed ID: 31617178
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting long non-coding RNAs in cancer therapy using CRISPR-Cas9 technology: A novel paradigm for precision oncology.
    Mahato RK; Bhattacharya S; Khullar N; Sidhu IS; Reddy PH; Bhatti GK; Bhatti JS
    J Biotechnol; 2024 Jan; 379():98-119. PubMed ID: 38065367
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.